Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human interleukin-2 messenger RNA + aNP-HMJ1
- Development stage
- Preclinical
- Lead developer
- Biotrip
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
human interleukin-2 messenger RNA + aNP-HMJ1 is an experimental cancer immunotherapy comprising messenger RNA (mRNA) encoding human interleukin-2 (hIL-2) encapsulated within apolipoprotein A1 nanoparticles (aNPs) that utilize the proprietary ionizable lipid HMJ1. Developed by Biotrip in collaboration with Eindhoven University of Technology and Radboud University Medical Center, the platform is designed for the targeted delivery of cytokine-encoding mRNA to secondary lymphoid organs, such as the spleen and lymph nodes, while minimizing off-target expression in the liver. This localized production of hIL-2 is intended to expand and activate cytotoxic CD8+ T cells, enhancing their anti-tumor effects without the systemic toxicities associated with traditional recombinant IL-2 therapy. Preclinical studies in melanoma and colorectal cancer models have demonstrated significant tumor growth inhibition and complete remissions, supported by biodistribution data in non-human primates.
- Other names
- hIL2-mRNA-loaded aNP-HMJ1hIL-2-mRNA-loaded aNP-HMJ1hIL 2-mRNA-loaded aNP-HMJ1mRNA-loaded apolipoprotein nanoparticles
02
Targets
IL2RA (Interleukin-2 receptor alpha subunit)IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on human interleukin-2 messenger RNA + aNP-HMJ1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human interleukin-2 messenger RNA + aNP-HMJ1.